Healthcare Services in Libya, 2022–2026

From Domestic Service Gaps to a Major Cross-Border Medical Care Market

Libya’s healthcare market between 2022 and 2026 can be understood through two parallel realities: the domestic healthcare system and the rapidly expanding cross-border healthcare market created by Libyan patients travelling abroad to obtain medical services.

The domestic system continues to provide essential primary, secondary and emergency services, but faces challenges related to specialized clinical capacity, medical technology, medicines, qualified personnel, maintenance and continuity of care.

At the same time, thousands of Libyan patients travel abroad when a required medical service is unavailable, delayed, insufficiently developed, or perceived to be available at a higher quality in another country.

The most important destinations are Tunisia, Egypt and Turkey, followed by Jordan, Germany and Italy.

Libya’s Therapeutic Services Support and Development Agency identifies Tunisia, Egypt, Jordan, Turkey, Germany and Italy among the foreign destinations used for medical treatment.

1. Understanding the Libyan Healthcare Market

Libya has a distinctive healthcare-market structure. Its oil-based economy gives the country the potential to finance substantial healthcare expenditure, while its relatively small population creates the possibility of significant healthcare expenditure per capita.

However, the central challenge is not simply the amount of money available for healthcare. The more fundamental issue is whether the country possesses sufficient clinical capacity, infrastructure, technology, specialists and healthcare-management systems to convert financial resources into accessible and high-quality medical services.

A healthcare system may possess hospitals, physicians and medical equipment while still experiencing significant service gaps when it cannot consistently provide advanced specialized care.

This is particularly relevant to:

• Advanced oncology
• Radiotherapy
• Complex cardiovascular procedures
• Cardiac surgery
• Advanced pediatric care
• Neurosurgery
• Organ transplantation
• Complex orthopedic surgery
• Fertility treatment
• Advanced diagnostic imaging
• Specialized laboratory diagnostics
• Rehabilitation
• Complex intensive care
• Rare-disease management

When these services are not consistently available domestically, healthcare expenditure moves across borders.

When domestic healthcare capacity does not match patient demand, healthcare expenditure does not disappear—it moves across borders.

2. Healthcare Service Provision Inside Libya

Between 2022 and 2026, Libya continued to depend heavily on its public healthcare infrastructure while private healthcare providers increasingly supplemented the system.

Primary Healthcare

Primary healthcare includes:

• Family medicine
• General practice
• Maternal and child health
• Vaccination
• Chronic disease management
• Basic laboratory services
• Basic diagnostic imaging
• Preventive healthcare

These services are particularly important because Libya, like other countries in the region, faces a growing need for continuous management of chronic diseases rather than episodic treatment.

Secondary Healthcare

Secondary services include:

• General surgery
• Internal medicine
• Obstetrics and gynecology
• Pediatrics
• Emergency medicine
• General cardiology
• Orthopedics
• Ophthalmology
• ENT
• Urology
• Diagnostic imaging
• Laboratory medicine

Private clinics and hospitals play an increasingly important role in delivering these services, particularly in major population centers.

Tertiary and Quaternary Healthcare

The greatest service gap is generally found in highly specialized tertiary and quaternary medicine.

Advanced medical services require:

• Sophisticated medical equipment
• Experienced multidisciplinary teams
• Specialized nurses
• Advanced pharmaceuticals
• Continuous professional training
• High-volume clinical activity
• Clinical protocols
• Quality assurance systems
• Advanced intensive care

Where these elements are not consistently available, patients are more likely to be referred abroad.

3. The Real Healthcare Export: Libyan Patients

The most important feature of the Libyan healthcare market is therefore not only what happens inside Libyan hospitals.

It is what happens after the patient leaves Libya.

A typical cross-border medical journey may include:

1. Initial physician consultation in Libya
2. Diagnostic imaging or laboratory testing
3. Specialist referral
4. Government authorization or private financing
5. International travel
6. Admission to a foreign hospital
7. Surgery or medical treatment
8. Accommodation for the patient
9. Accommodation for accompanying relatives
10. Post-treatment follow-up
11. Return travel
12. Additional treatment when required

The economic value of medical travel is therefore significantly larger than the hospital invoice alone.

4. Why Do Libyans Travel Abroad for Healthcare?

4.1 Availability of Specialized Services

The most fundamental reason for international treatment is the lack of consistent access to some specialized services within Libya.

4.2 Advanced Medical Technology

Foreign hospitals may offer access to:

• Advanced radiotherapy
• Robotic surgery
• PET-CT
• Advanced cardiac catheterization
• Electrophysiology
• Advanced fertility technology
• Molecular oncology
• Specialized intensive care
• Advanced neurosurgery

4.3 Specialist Availability

Patients may seek specialists with high procedure volumes, international experience and access to multidisciplinary teams.

4.4 Continuity of Care

Complex diseases often require a complete treatment pathway rather than a single medical procedure. Patients may therefore select a healthcare system capable of providing diagnosis, treatment, surgery, rehabilitation and follow-up under one coordinated model.

4.5 Perception of Quality

Patient confidence is one of the strongest drivers of international medical travel.

Even when a particular service exists in Libya, patients may prefer foreign providers because they perceive them as offering:

• Better clinical outcomes
• More experienced physicians
• Advanced technology
• Stronger accreditation
• Better nursing services
• More reliable medicines
• Better postoperative care

4.6 Geographic and Cultural Factors

Tunisia and Egypt have major advantages because of their geographical proximity, direct transportation links, cultural familiarity, Arabic language and established relationships with Libyan patients.

5. Tunisia: Libya’s Largest Medical Treatment Destination

Tunisia is arguably the most strategically important foreign healthcare market for Libya.

Its advantages include:

• Geographical proximity
• Short travel times
• Extensive private healthcare infrastructure
• Established Libyan patient base
• Competitive treatment prices
• Strong private hospital sector
• Established medical tourism infrastructure

The oncology data demonstrates Tunisia’s importance.

In 2023, approximately 11,768 Libyan oncology patients were reported to have been treated in Tunisia.

This was substantially higher than the number reported in any other destination.

In early 2024, another Libyan government snapshot reported approximately 4,416 oncology patients in Tunisia, compared with 970 in Egypt, 186 in Turkey and 48 in Germany.

Tunisia therefore represents the first major external extension of Libya’s healthcare system.

6. Egypt: A Major Healthcare Destination

Egypt represents another critical destination for Libyan patients.

Egypt’s competitive advantages include a very large healthcare ecosystem comprising:

• University hospitals
• Private hospitals
• Specialized medical centers
• Oncology centers
• Cardiac centers
• Fertility centers
• Orthopedic hospitals
• Neurosurgery centers
• Pediatric services
• Rehabilitation facilities
• Laboratory networks
• Diagnostic imaging networks

In 2023, approximately 2,292 Libyan oncology patients were reported to be receiving treatment in Egypt.

Egypt is particularly attractive to patients from eastern Libya because of geographical proximity and regional connectivity.

The continuing presence of Libyan healthcare-management structures in Cairo and discussions regarding contracts with Egyptian hospitals demonstrate that Egypt is not simply an incidental destination.

7. Turkey: The Premium Regional Alternative

Turkey has emerged as an important destination for Libyan patients seeking sophisticated private healthcare.

Its strengths include:

• Advanced hospitals
• Internationally oriented healthcare providers
• Modern medical technology
• Cardiovascular medicine
• Oncology
• Transplantation
• Neurosurgery
• Orthopedics
• Fertility treatment
• Complex surgery
• Intensive care

In 2023, approximately 1,187 Libyan oncology patients were reported in Turkey.

Turkey occupies a different strategic position from Tunisia and Egypt.

Tunisia and Egypt are primarily proximity-and-access markets, while Turkey increasingly represents a technology-and-specialization market.

8. Jordan

Jordan is another important destination identified by Libyan healthcare authorities.

Its strengths include:

• Specialist hospitals
• Oncology
• Cardiology
• Orthopedics
• Rehabilitation
• Pediatric medicine
• Private healthcare
• Arabic-language medical services

Jordan has historically served patients from across the Arab world and continues to occupy an important position in the regional medical tourism market.

9. Germany and Italy

European destinations serve a smaller but strategically important segment of Libyan patients.

These destinations are generally associated with:

• Highly complex cases
• Difficult diagnoses
• Specialized surgery
• Rare diseases
• Advanced oncology
• University medicine
• Advanced second opinions
• Highly specialized technology

The smaller patient numbers compared with Tunisia, Egypt and Turkey reflect the higher cost and logistical complexity of European treatment.

10. The Most Popular Countries for Libyan Medical Treatment

11. Oncology: A Major Driver of Medical Travel

Cancer treatment is one of the clearest illustrations of Libya’s external healthcare dependence.

In 2023, approximately 16,000 Libyan oncology patients were reportedly referred abroad.

Reported treatment costs ranged from approximately US$2,000 to US$50,000 per patient, depending on the disease and treatment requirements.

This range demonstrates why medical-travel expenditure cannot be calculated simply by multiplying patient numbers by a single average hospital bill.

12. The Cost of Medical Treatment Abroad

There is no comprehensive publicly available annual national account covering all Libyan healthcare expenditure incurred abroad between 2022 and 2026.

This is an important limitation when attempting to calculate the size of the market.

Official expenditure may include:

• Government-funded patients
• Approved treatment cases
• Foreign healthcare office payments
• Embassy medical-office payments
• Hospital contracts
• Direct deposits to foreign providers

However, it may not fully capture:

• Privately financed patients
• Cash payments
• Companion expenditure
• Hotels
• Transportation
• Air ambulance
• Pharmaceutical purchases
• Second opinions
• Follow-up treatment
• Unregistered medical travel

Therefore, any national market estimate should be presented as a range rather than a single definitive number.

13. Estimated Medical Spending Abroad, 2022–2026

Based on available evidence from patient volumes, treatment costs, historical expenditure estimates and foreign-provider liabilities, the following represents a reasonable analytical scenario.

A more conservative estimate focused primarily on direct medical treatment would be approximately US$750 million–US$1.25 billion during 2022–2026.

When accommodation, transportation, companions and other associated expenses are included, the broader economic value could approach US$1.0–1.5 billion.

14. Evidence of the Financial Scale

The financial pressure can also be observed through Libya’s relationships with foreign healthcare providers.

In 2024, the head of Tunisia’s National Union Chamber of Private Clinics reported that Libya owed approximately US$111 million to 60 Tunisian private clinics for the treatment of Libyan patients.

Other reports have identified substantial outstanding liabilities associated with treatment in Tunisia and Turkey.

This highlights a critical point:

Foreign healthcare spending is not only a patient-flow issue; it is also a public-finance, healthcare-procurement and claims-management issue.

15. Government-Funded Versus Private Medical Travel

Government-Funded Treatment

Government-funded patients may receive treatment through:

• Treatment authorization
• Foreign health offices
• Embassy medical offices
• Hospital contracts
• Direct deposits
• Formal referral mechanisms

Private Medical Travel

A second category consists of patients who finance their treatment privately.

These patients may travel because they:

• Want faster treatment
• Prefer a particular physician
• Require a service unavailable locally
• Want a second opinion
• Have family relationships abroad
• Prefer a specific foreign hospital
• Can afford private international healthcare

The private market is difficult to measure and therefore means that official government figures almost certainly represent only part of total Libyan medical travel.

16. The Hidden Cost: The Patient Is Not Traveling Alone

Medical-travel economics should never be calculated solely from the hospital invoice.

A Libyan patient may travel with a spouse, parent, child, sibling or caregiver.

The total economic cost may therefore include:

• Medical treatment
• Accommodation
• Food
• Transportation
• Flights
• Visa and documentation costs
• Companion expenses
• Medical assistance
• Post-treatment care
• Repeat travel

The actual economic leakage from Libya can therefore be considerably greater than the amount paid directly to a foreign hospital.

17. Tunisia Versus Egypt Versus Turkey

18. From Medical Travel to Cross-Border Healthcare Management

The future market should not be viewed simply as:

Libyan Patient → Foreign Hospital

A more sophisticated model is:

Libyan Payer → Healthcare Coordinator → Foreign Specialist → Foreign Hospital → Libyan Follow-Up Provider

This creates opportunities for:

• Medical tourism management companies
• International patient departments
• Healthcare insurance
• Third-party administrators
• Medical assistance companies
• Second-opinion platforms
• Telemedicine
• Cross-border electronic medical records
• Medical transportation
• Patient accommodation
• International healthcare contracting

19. The Opportunity to Localize Treatment

The Libyan government has increasingly promoted the localization of treatment by developing domestic capacity and reducing dependence on foreign treatment.

The strategy is particularly relevant for services that have:

• High patient volumes
• High annual expenditure abroad
• Strong clinical demand
• Potential for domestic development
• Available international expertise

Recent examples of international medical teams working inside Libya demonstrate that the country can potentially import expertise instead of exporting patients.

20. The Five-Year Strategic Question

The key question for Libya between 2026 and 2030 should not simply be:

“How can Libya stop patients from travelling abroad?”

A more strategic question is:

“Which treatments should Libya localize, which should remain regional, and which should remain international?”

Not every complex treatment needs to be developed domestically.

Libya should prioritize services according to:

1. Patient volume
2. Clinical urgency
3. Expenditure abroad
4. Feasibility of localization
5. Availability of specialists
6. Technology requirements
7. Expected return on investment
8. Quality and safety
9. Long-term sustainability
10. Potential for public-private partnership

21. Highest-Priority Localization Opportunities

1. Oncology

• Chemotherapy
• Radiotherapy
• Oncology surgery
• PET-CT
• Molecular diagnostics
• Targeted therapy
• Multidisciplinary tumor boards

2. Cardiovascular Care

• Cardiac catheterization
• PCI
• Electrophysiology
• Cardiac surgery
• Vascular surgery
• Advanced cardiac imaging

3. Fertility

• IVF
• ICSI
• Reproductive endocrinology
• Advanced embryology laboratories

4. Advanced Diagnostics

• PET-CT
• Advanced MRI
• Molecular pathology
• Genetic testing
• Specialized laboratory diagnostics

5. Orthopedics

• Joint replacement
• Spine surgery
• Sports medicine
• Complex trauma

6. Neurosurgery

• Brain tumors
• Vascular neurosurgery
• Complex spine surgery
• Neurointervention

7. Pediatric Specialties

• Pediatric cardiac surgery
• Pediatric oncology
• Neonatal intensive care
• Pediatric surgery

22. A New Libyan Healthcare Business Model

Libya could potentially transform part of its medical-travel expenditure into domestic healthcare investment.

For example, if annual expenditure abroad is assumed at US$200–300 million, redirecting only 30% toward domestic healthcare development would represent approximately:

Over five years, this could represent approximately:

Such capital could support:

• Specialized hospitals
• Oncology centers
• Cardiac centers
• Diagnostic networks
• Medical laboratories
• Rehabilitation facilities
• Training centers
• Medical technology
• Digital health infrastructure

The objective should not be to eliminate international treatment. It should be to optimize where the money is spent.

23. International Treatment Will Remain Necessary

Even a highly developed Libyan healthcare system will continue to require international referrals.

International treatment will remain appropriate for:

• Rare diseases
• Highly complex transplantation
• Experimental therapies
• Selected pediatric conditions
• Unusual cancers
• Highly specialized neurosurgery
• Complex genetic disorders
• Advanced clinical trials

The strategic objective should therefore be:

24. The Role of Insurance

Insurance could fundamentally change Libya’s healthcare-financing model.

A mature healthcare-financing system could establish two integrated networks.

Domestic Network

Primary Care → Specialist Care → Hospital Care → Advanced Diagnostics

International Network

Second Opinion → Complex Surgery → Selected Oncology → Rare Disease → Advanced Tertiary Care

The payer could negotiate:

• Bundled prices
• Case rates
• DRG-type payment mechanisms
• Annual provider contracts
• Negotiated hospital tariffs
• Clinical quality requirements
• Outcome reporting

Instead of paying uncontrolled foreign hospital bills, Libya could establish structured International Provider Networks with pre-negotiated prices and defined clinical pathways.

25. The Potential Role of TPAs

Third-Party Administrators could become particularly important in managing cross-border healthcare.

A TPA could manage:

• Patient eligibility
• Medical necessity
• Prior authorization
• Hospital selection
• Travel arrangements
• Admission
• Treatment monitoring
• Billing
• Claims management
• Discharge
• Follow-up
• Medical records

This could significantly reduce financial leakage and improve control over international healthcare expenditure.

The system could move from:

“Send the patient abroad and pay the bill.”

to:

“Manage the entire international episode of care.”

26. The Strategic Opportunity for Egypt

For Egypt, the Libyan healthcare market represents an important cross-border healthcare opportunity.

Egypt already possesses:

• Large hospital capacity
• University medicine
• Private hospitals
• Specialist physicians
• Diagnostic networks
• Pharmaceutical manufacturing
• Medical laboratories
• Rehabilitation services
• Fertility services
• Oncology services
• Cardiac services

The Libyan patient base provides an opportunity to establish dedicated Libya Healthcare Programs within Egyptian hospitals.

Such programs could provide:

• Dedicated Libyan patient coordinators
• International patient departments
• Bundled treatment prices
• Dedicated appointment channels
• Accommodation packages
• Airport transfers
• Medical-record coordination
• Post-discharge follow-up in Libya

27. The Strategic Opportunity for Tunisia

Tunisia is particularly well positioned to remain Libya’s leading cross-border healthcare partner because of geography and its established patient flows.

The next stage should move beyond individual patients toward:

Institution-to-Institution Healthcare Partnerships

• Hospital networks
• Oncology centers
• Rehabilitation centers
• Specialized clinics
• Insurance companies
• TPAs
• Telemedicine providers

28. The Strategic Opportunity for Turkey

Turkey can continue positioning itself as a premium destination for complex and technology-intensive healthcare.

Its major opportunities include:

• Advanced oncology
• Cardiovascular medicine
• Transplantation
• Neurosurgery
• Orthopedics
• Fertility
• Robotic surgery
• Advanced diagnostics

29. Market Outlook: 2026–2030

The Libyan healthcare market is likely to develop along three simultaneous paths.

This creates a hybrid healthcare model:

Local Healthcare + Regional Healthcare + International Healthcare

30. Key Market Indicators to Monitor

Investors, healthcare operators, insurers and policymakers should monitor:

• Number of Libyan patients treated abroad
• Expenditure by destination
• Expenditure by specialty
• Government versus private funding
• Average cost per case
• Average length of stay
• Companion costs
• Outstanding foreign-provider bills
• Number of foreign-provider contracts
• Number of procedures localized
• Domestic treatment success rates
• Medical evacuation volume
• Oncology referrals
• Cardiac referrals
• Fertility referrals
• Orthopedic referrals

Conclusion

The Libyan healthcare market between 2022 and 2026 is best understood as a dual-market healthcare economy.

One market exists inside Libya.

The second market exists outside Libya and is supplied by foreign hospitals treating Libyan citizens.

Tunisia, Egypt and Turkey dominate this external market, while Jordan, Germany and Italy serve more specialized segments.

The available evidence demonstrates the scale of this phenomenon. Thousands of Libyan oncology patients alone have been treated abroad, with Tunisia accounting for the largest share. In 2023, approximately 16,000 oncology patients were reported to have been referred abroad, while treatment costs reportedly ranged from approximately US$2,000 to US$50,000 per patient.

Foreign-provider debts further demonstrate the financial significance of the market, including reported liabilities to Tunisian private clinics.

This estimate should be treated as an analytical market-sizing range rather than an official national expenditure account because Libya does not currently publish a comprehensive annual account covering every category of international medical spending.

The strategic opportunity for Libya is therefore enormous.

The country does not necessarily need to eliminate medical travel.

It needs to manage it strategically.

The future Libyan healthcare system should determine which services must be developed domestically, which should be delivered through regional partnerships with Tunisia, Egypt and Turkey, and which complex cases should continue to be referred to Europe and other advanced healthcare markets.

The ultimate objective is not to stop international healthcare.

It is to ensure that every Libyan patient receives the right treatment, from the right provider, at the right cost, in the right location.